• SANUWAVE forecast Q2 2026 revenue of $9.6-$9.8 million, topping the revised guidance range of $8.5-$9.5 million.
• Preliminary Q2 revenue implies a 3%-5% decline from $10.1 million in Q2 2025.
• Management cited headwinds in capital sales from customer stress, partly offset by record consumable applicator unit sales and revenue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SANUWAVE Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607131630PRIMZONEFULLFEED9761175) on July 13, 2026, and is solely responsible for the information contained therein.